IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 30, 2022 | Post-IPO Equity | $300M | — | — | — | Detail |
Jul 26, 2022 | Post-IPO Debt | $250M | 2 | Hercules Capital Silicon Valley Bank | — | Detail |
Jul 13, 2021 | Post-IPO Equity | $100.20M | — | — | — | Detail |
Jan 1, 2020 | Post-IPO Equity | — | 1 | — | — | Detail |
Jan 24, 2014 | Post-IPO Equity | $41.70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | Yes | Post-IPO Debt |
Silicon Valley Bank | Yes | Post-IPO Debt |
Sofinnova Investments | Yes | Series Unknown |
Clarus Ventures | Yes | Series B |
Frazier Healthcare Partners | — | Post-IPO Equity |
Novo Holdings | — | Post-IPO Equity |
HBM Healthcare Investments AG | — | Series B |
SV Health Investors | — | Series B |